Transcatheter Therapies for the Treatment of Valvular and Paravalvular Regurgitation in Acquired and Congenital Valvular Heart Disease

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:66

Review

Ruiz, Carlos E.¹  Kliger, Chad¹  Perk, Gila¹  Maisano, Francesco²  Cabalka, Allison K.³  Landzberg, Michael⁴  Rihal, Chet³  Kronzon, Itzhak¹ 

[1] Hofstra Sch Med, Lenox Hill Heart & Vasc Inst New York, New York, NY USA

[2] Univ Zurich Hosp, Dept Cardiothorac Surg, CH-8091 Zurich, Switzerland

[3] Mayo Clin, Dept Cardiol, Rochester, MN USA

[4] Harvard Univ, Adult Congenital Heart Dis, Boston Childrens Hosp, Boston, MA 02115 USA

关键词: aortic regurgitation;    mitral regurgitation;    pulmonic regurgitation;    transcatheter valve technology;    tricuspid regurgitation;   

DOI  :  10.1016/j.jacc.2015.05.034

来源: Elsevier

【 摘 要 】

Transcatheter therapies in structural heart disease have evolved tremendously over the past 15 years. Since the introduction of the first balloon-expandable valves for stenotic lesions with implantation in the pulmonic position in 2000, treatment for valvular heart disease in the outflow position has become more refined, with newer-generation devices, alternative techniques, and novel access approaches. Recent efforts into the inflow position and regurgitant lesions, with transcatheter repair and replacement technologies, have expanded our potential to treat a broader, more heterogeneous patient population. The evolution of multimodality imaging has paralleled these developments. Three-and 4-dimensional visualization and concomitant use of novel technologies, such as fusion imaging, have supported technical growth, from pre-procedural planning and intraprocedural guidance, to assessment of acute results and follow-up. A multimodality approach has allowed operators to overcome many limitations of each modality and facilitated integration of a multidisciplinary team for treatment of this complex patient population. (C) 2015 by the American College of Cardiology Foundation.

【 授权许可】

Free